Using radiolabeled girentuximab in patient-derived liver metastasis organoids (PDOs) and xenograft models, we then characterized the preclinical utility of CA-IX imaging and therapeutic targeting in mCRC.<h4>Results</h4>CA-IX mRNA and/or protein expression was detected in 87% of CRC liver metastasis samples, with little to no expression in surrounding liver tissue. This evidence concerns the gene CA9 and colorectal carcinoma.